CURLF Curaleaf Holdings, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1756770 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-0.9%
TTM net income YoY23.4%
TTM EPS YoY17.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR—
Margins
Gross margin48.0%
Operating margin1.9%
Net margin-16.1%
FCF margin5.3%
EBITDA margin19.2%
Returns
ROE-22.5%
ROA-7.1%
ROIC (approx.)1.4%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets66.3%
Debt / equity0.66x
Current ratio1.12x
Interest coverage0.47x
Cash quality & payout
Operating cash flow / net income-0.76x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue6.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026-03-312026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2021Q42021-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $352.65M | $340.10M | — | $333.07M | $317.86M | $310.59M | — | — |
| Cost of revenue | $182.17M | $170.19M | — | $171.27M | $157.28M | $157.50M | — | — |
| Gross profit | $170.48M | $169.91M | — | $161.79M | $160.58M | $153.08M | — | — |
| SG&A expense | $131.03M | $131.68M | — | $87.75M | $118.51M | $111.36M | — | $100.26M |
| Operating income | $2.94M | $4.22M | — | $2.92M | $6.92M | $6.25M | — | — |
| Interest expense | — | — | — | $12.78M | $13.57M | $13.67M | — | — |
| Pretax income | -$22.86M | -$26.31M | — | -$24.13M | -$21.42M | -$16.27M | — | — |
| Income tax | $14.51M | -$38.78M | — | $25.36M | $32.83M | $31.84M | — | — |
| Net income | -$32.72M | $12.51M | $69.80M | -$59.82M | -$57.03M | -$53.16M | -$61.06M | — |
| EBITDA | $54.48M | $52.83M | — | $52.54M | $55.91M | $55.41M | — | — |
| EPS (basic) | -0.12 | 0.05 | — | — | -0.25 | -0.26 | — | — |
| EPS (diluted) | -0.12 | 0.05 | — | — | -0.25 | -0.26 | — | — |
| Weighted avg. shares (diluted) | 264.88M | 270.70M | — | — | 254.94M | 252.42M | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $92.39M | $94.59M | — | $89.21M | $92.80M | $87.75M | — | $299.33M |
| Receivables | $77.26M | $70.61M | — | $73.86M | — | — | — | $60.43M |
| Inventory | $239.87M | $244.72M | — | $225.02M | — | — | — | $248.15M |
| Current assets | $463.66M | $467.80M | — | $448.62M | — | — | — | $726.62M |
| PP&E, net | $501.06M | $505.90M | — | $520.39M | — | — | — | $525.83M |
| Goodwill | $638.29M | $633.02M | — | $635.12M | — | — | — | $571.65M |
| Intangibles | $940.76M | $956.07M | — | $1.01B | — | — | — | $1.04B |
| Total assets | $2.79B | $2.81B | — | $2.85B | — | — | — | $3.11B |
| Current liabilities | $287.81M | $307.11M | — | $294.31M | — | — | — | $316.24M |
| Short-term debt | $46.05M | $41.01M | — | $35.73M | — | — | — | $1.97M |
| Long-term debt | $583.43M | $570.53M | — | $512.92M | — | — | — | $457.92M |
| Total debt | $629.48M | $611.54M | — | $548.65M | — | — | — | $459.88M |
| Total liabilities | $1.95B | $1.95B | — | $2.01B | — | — | — | $1.44B |
| Shareholders' equity | $847.02M | $867.46M | $821.11M | $756.35M | $814.82M | $871.29M | $814.02M | $1.55B |
| Net debt | $537.09M | $516.95M | — | $459.44M | — | — | — | $160.55M |
| Shares outstanding | 264.98M | 264.74M | — | 257.49M | — | — | — | 708.34M |
| Cash flow statement | ||||||||
| Operating cash flow | $21.10M | — | — | $43.02M | $47.70M | — | — | — |
| Capital expenditure | $17.07M | — | — | $16.53M | $16.11M | — | — | — |
| Free cash flow | $4.03M | — | — | $26.49M | $31.59M | — | — | — |
| Investing cash flow | -$18.73M | — | — | -$19.31M | -$17.23M | — | — | — |
| Financing cash flow | -$4.33M | — | — | -$28.94M | -$25.73M | — | — | — |
| Depreciation & amortization | $51.54M | $48.61M | — | $49.62M | $48.99M | $49.16M | — | — |
| Stock-based compensation | $14.04M | $10.27M | — | $12.34M | $10.29M | $8.48M | — | — |
| Share buybacks | $1.00M | — | — | — | $0 | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.